---
title: "REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295155257.md"
description: "REGENXBIO Inc.'s average 12-month price target was raised to $26.17 by 12 analysts, implying a 149% upside from the Aug. 5 close. The consensus rating remains 'Buy', with 11 analysts recommending Buy, 1 Hold, and 0 Sells. Price forecasts range from $10 to $50 per share."
datetime: "2026-08-06T23:20:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295155257.md)
  - [en](https://longbridge.com/en/news/295155257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295155257.md)
generator: "portal-rs"
---

# REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside

-   According to estimates from 12 analysts, REGENXBIO Inc. stock's average price target has risen from $26 to $26.17, with forecasts ranging from $10 to $50 per share
-   Based on the Aug. 5 closing price, the updated target implies approximately 149% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 11 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for REGENXBIO Inc. on the , and track all previous and future analyst recommendations for REGENXBIO Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Regenxbio director Gregory Austin Ciongoli files initial beneficial ownership statement](https://longbridge.com/en/news/297240097.md)
- [FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome](https://longbridge.com/en/news/296779641.md)
- [RegenXBio Faces RGX-121 Clinical Hold, Refocuses Pipeline](https://longbridge.com/en/news/296834397.md)
- [Tribe Property Technologies Inc. reports Q2 results](https://longbridge.com/en/news/296953133.md)
- [REGENXBIO elects Gregory Ciongoli as director; Jean Bennett and. "Jerry" Karabelas resign](https://longbridge.com/en/news/296955594.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**